KRAS and cancer: For example, a recent study showed that KRAS mutation plays an important role in the metabolic reprogramming of cancer cells, shifting them towards an anabolic metabolism and support unconstrained proliferation, leading to reduced activity of both gemcitabine and paclitaxel [33,34].